Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mulligan

Showing results (501-510 of 529) with videos related to

Pageof 53
Sort By:
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 VaccinationPeter M Izmirly, Mimi Y Kim, Marie Samanovic, et al.
Nature Immunology|January 2, 2025
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humansMario Cortese, Thomas Hagan, Nadine Rouphael, et al.
The Journal of Experimental Medicine|January 12, 2011
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionJens Wrammert, Dimitrios Koutsonanos, Gui-Mei Li, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 16, 2018
A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human <i>Mycobacterium tuberculosis</i> InfectionWendy E Whatney, Neel R Gandhi, Cecilia S Lindestam Arlehamn, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2015
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United StatesColleen S Kraft, Angela L Hewlett, Scott Koepsell, et al.
Academic Pathology|May 20, 2021
The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 PandemicJames M Crawford, Maria E Aguero-Rosenfeld, Ioannis Aifantis, et al.
Pageof 53

Showing results (501-510 of 529) with videos related to

Sort By:
Pageof 53
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 VaccinationPeter M Izmirly, Mimi Y Kim, Marie Samanovic, et al.
Nature Immunology|January 2, 2025
System vaccinology analysis of predictors and mechanisms of antibody response durability to multiple vaccines in humansMario Cortese, Thomas Hagan, Nadine Rouphael, et al.
The Journal of Experimental Medicine|January 12, 2011
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infectionJens Wrammert, Dimitrios Koutsonanos, Gui-Mei Li, et al.
The Lancet. Microbe|October 7, 2024
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trialRichard T Davey, Gary L Collins, Nadine Rouphael, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 27, 2024
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US AdultsChristina A Rostad, Robert L Atmar, Emmanuel B Walter, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 16, 2018
A High Throughput Whole Blood Assay for Analysis of Multiple Antigen-Specific T Cell Responses in Human <i>Mycobacterium tuberculosis</i> InfectionWendy E Whatney, Neel R Gandhi, Cecilia S Lindestam Arlehamn, et al.
The New England Journal of Medicine|October 9, 2013
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccineScott M Hammer, Magdalena E Sobieszczyk, Holly Janes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2015
The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United StatesColleen S Kraft, Angela L Hewlett, Scott Koepsell, et al.
Academic Pathology|May 20, 2021
The New York State SARS-CoV-2 Testing Consortium: Regional Communication in Response to the COVID-19 PandemicJames M Crawford, Maria E Aguero-Rosenfeld, Ioannis Aifantis, et al.
Pageof 53